Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

(2013) Sender Herschorn et al.   UROLOGY

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

(2012) Adrian Wagg et al.   BJU INTERNATIONAL

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder

(2010) Rufus Cartwright et al.   BJU INTERNATIONAL

SOLIFENACIN IN THE TREATMENT OF URGENCY AND OTHER SYMPTOMS OF OVERACTIVE BLADDER: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RISING-DOSE TRIAL

(2009)   BJU INTERNATIONAL

The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study

(2009) Karin S. Coyne et al.   BJU INTERNATIONAL

Patient-reported reasons for discontinuing overactive bladder medication

(2009) Joshua S. Benner et al.   BJU INTERNATIONAL

Basic Mechanisms of Urgency: Preclinical and Clinical Evidence

(2009) Martin C. Michel et al.   EUROPEAN UROLOGY

Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials

(2009) D. R. Staskin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study

(2008) Karin S. Coyne et al.   BJU INTERNATIONAL

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial

(2008) Linda Cardozo et al.   BJU INTERNATIONAL

Persistence of antimuscarinic drug use

(2008) Søren Brostrøm et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

(2008) N. Zinner et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Unknown

(2008) L. A. Leon et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Catecholamines Relax Detrusor through  2-Adrenoceptors in Mouse and  3-Adrenoceptors in Man

(2008) M. Wuest et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS